Építés alatt – nem éles oldal
Belépés
BefejeződöttFázis nélkül

Transcranial Magnetic Stimulation for the Treatment of Veterans With Alcohol Use Disorders

A legfontosabb adatok

Ki végzi
VA Office of Research and Development
Hol
Palo Alto (Egyesült Államok)A helyszín megnézése
Azonosító
Állapot
Befejeződött
Résztvevők
49 fő vett részt
Kezdés
2018. ápr. 15.
Befejezés
2024. jún. 28.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport egy már használt kezelést kap, összehasonlításként.
A vizsgált kezelések
  • Active rTMS
  • Sham rTMS
A regiszteradat frissítve
2026. január 28.

Ki vehet részt

Életkor
21 év – 65 év
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 31 feltétel megnézéseKevesebb

Ki vehet részt

  • The study will be open to male and females, regardless of race and ethnic origin, who are in active treatment for an alcohol use disorder (AUD)
  • Meet Diagnostic and Statistical Manual of Mental Disorders, 5th Edition criteria for AUD, and alcohol is self-identified as primary substance of misuse
  • Actively in treatment at VA Palo Alto HCS Addiction Treatment Service, and able to read, verbalize understanding, and voluntarily sign the Informed Consent Form prior to participation in study procedures
  • Participants will be accepted if taking medications specifically for the treatment of MDD, cigarette smoking, or for other psychiatric conditions; as long as the medications are not documented to lower seizure threshold; must be stable on any psychotropic medication for at least 1 month prior to enrollment; it would be clinically contraindicated to require participants to discontinue such medications for research
  • Participants will be abstinent from alcohol and non-prescribed substances for at least 7 consecutive days prior to active or sham rTMS and no participant demonstrates active acute withdrawal symptoms

Ki nem vehet részt

  • Current use of an FDA approved medication for treatment of AUD, i.e.:; disulfiram; acamprosate; naltrexone
  • Active current suicidal intent or plan; patients with a previous clinical flag for risk for suicide will be required to have an established safety plan involving their primary psychiatrist and the treatment team before entering the clinical trial
  • Any form of previous rTMS or electroconvulsive treatment; Biomedical:
  • Other severe cardiac illness as defined by treatment regimen changes in the prior 3 months
  • Any biomedical implants with ferromagnetic content
  • Psychiatric:
  • History of Schizophrenia Spectrum Disorders
  • Bipolar Disorders
  • A current substance use disorder that exceeds the severity of the AUD; based on DSM-5 diagnostic criteria
  • Including but not limited to uncontrolled thyroid disease
  • Unstable congestive heart failure
  • Angina
  • Cancer if < 1 year since end of treatment
  • Unstable diabetes
  • Alzheimer's disease
  • Parkinson's disease
  • Cardiac pacemakers or any magnetic resonance contraindications
  • Any primary or traumatically induced seizure disorder; General:
  • Wechsler Adult Reading Test below the 7th percentile, i.e.:; moderate or greater impairment in estimated general intelligence
  • Current use of any medication or substance that is documented to lower seizure threshold or has been identified as a contraindication for rTMS treatment
  • Cerebrovascular accident
  • COPD requiring oxygen supplementation
  • Neurostimulation devices
  • Traumatic brain injury with self-reported or observed loss of consciousness > 30 minutes
  • Lack of fluency in English
  • Females who are pregnant or actively attempting pregnancy; conservative exclusion for magnetic resonance research

Helyszínek itt: Egyesült Államok

  • VA Palo Alto Health Care System, Palo Alto, CAPalo Alto, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

At least 60% of Veterans with an alcohol use disorder will relapse within 6 months of treatment, irrespective of the type of treatment they receive. This indicates that currently available interventions for treating AUD in Veterans are not effective in helping them achieve long-term sobriety. Repetitive transcranial magnetic stimulation (rTMS) is a brain stimulation method that is at the forefront of innovative, non-invasive, and safe treatments for AUD. However, there have been no studies that specifically determined the effectiveness of rTMS treatment for Veterans with AUD. This project will evaluate the effectiveness of rTMS treatment in promoting long-term abstinence in Veterans suffering from AUD. Assisting Veterans in achieving long-term and sustained sobriety is critical because it is associated with the best medical, cognitive, psychiatric, and psychosocial recovery from AUD.

A vizsgálat 2 csoportja

  • active rTMSMár használt kezelés, összehasonlításként

    Active rTMS will receive an intermittent rTMS stimulation protocol.

  • sham rTMSSzínlelt kezelés, összehasonlításként

    Sham rTMS will receive all conditions except the actual intermittent theta burst rTMS stimulation.

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Publikációk
A regiszteradat frissítve
2026. január 28.